SpringWorks Therapeutics Trading Volume Surges to 252nd Position Amid Merck Acquisition

On May 6, 2025, SpringWorks Therapeutics (SWTX) saw a significant increase in trading volume, with a total of $337 million in shares traded, marking a 92.24% rise from the previous day. This surge placed SpringWorks at the 252nd position in terms of trading volume for the day. However, the stock price experienced a slight decline, falling by 0.15%.

Merck KGaA, a prominent German pharmaceutical company, announced on Monday that it has reached an agreement to acquire SpringWorks Therapeutics, a U.S.-based biotech firm, for approximately $3.9 billion. This strategic move aims to bolster Merck's oncology pipeline and expand its presence in the biotech sector.

SpringWorks Therapeutics has been in the spotlight recently due to the potential acquisition by Merck KGaA. The deal, valued at around $3.9 billion, involves Merck acquiring SpringWorks for $47 per share in cash. This acquisition is expected to enhance Merck's oncology portfolio and provide SpringWorks with the resources to further develop its pipeline of cancer treatments.